A Comprehensive, Multinational GIST Registry

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversität Duisburg-Essen

About this trial

Patients diagnosed with a gastrointestinal stromal tumor (GIST), a rare type of tumor in the digestive tractparticipate in this scientific research study, known as a registry study, to help improve understanding and treatment of GIST.

This study collects medical information and biological samples-such as blood or tumor tissue-from patients. It does not involve new treatments, medications, or medical procedures. The patient's regular medical care will continue as usual, and participation will not require extra appointments or tests.

The study aims to learn more about how GIST behaves, especially in rare forms such as SDH-deficient or NF1-associated tumors. While targeted drugs are available for many patients, some tumors return or become resistant to treatment. By gathering data from many patients, researchers hope to better understand these challenges, identify risk factors for worse outcomes, and help design future studies and treatments-especially for rare types of GIST.

If the patient agrees to participate, information will be collected from their medical records, scans (such as CT or MRI), and doctor visits. They may be asked to complete optional questionnaires about their health and quality of life. If they consent, small blood samples (up to 50 ml) may be collected during routine check-ups. If surgery is needed, a small part of the tumor tissue may be stored for research. Other samples-such as saliva, stool, urine, or spinal fluid-may also be collected if they are taken during normal care, to study how bacteria in the body might affect the disease and treatment.

Participation is completely voluntary. The patient can choose to join or not, and can withdraw at any time without affecting their care or relationship with their doctor. Even if they do not agree to provide biological samples, they can still take part in the study by sharing medical data and scan results.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of a gastrointestinal stromal tumor (GIST)

Verbal and written informed consent for participation in the study with planned prospective data collection

Physical and mental ability to provide informed consent

Disqualifiers

Severe neurological or psychological illness that impairs the ability to give informed consent

Trial population

Patients of any age group with a diagnosis of gastrointestinal stromal tumor (GIST).

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 1 trial group
Group A: all patients with GIST regardless of disease status or molecular subtype

Trial outcomes

Primary outcomes

1

Creation of a prospective and retrospective, multi-center, international GIST cohort as a foundation for analyzing prognostic factors and planning future clinical trials.

Time frame
30 years

Secondary outcomes

1

Establishment of a comprehensive biobank with corresponding clinical, radiological, and histological data to support future research projects.

Time frame
30 years
2

Identification of risk factors relevant to the treatment and counseling of GIST patients.

Time frame
30 years
3

Identification of predictive factors for response to local and systemic therapies.

Time frame
30 years
4

Characterization of resistance mechanisms.

Time frame
30 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: